Prof. David J Adams (from Experimental Cancer Genetics, Sanger Institute, Hinxton, Cambridge, UK; Department of Haematology, University of Cambridge, Hills Road, Cambridge, UK; Cambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge, UK) has published a paper in the Journal Nature genetics stating that “Inactivating Cux1 mutations promote tumorigenesis.” This study suggests that: 1) CUX1 mutations promote tumorigenesis; 2) CUX1 is mutated in ~1–5% of various tumors; and 3) CUX1 deficiency activates the phosphoinositide 3-kinase (PI3K) pathway. In connection with this finding, Dr L Boominathan, Director-cum-chief scientist of GBMD, reports that: Tumorigenesis: Oct-4 and Sox2 suppress the expression of a new tumor suppressor gene CUX1 via induction of their target gene, 26/December/2013, 4.28 am. This study may explain how oncogenic/reprogramming factors such as Oct-4 and Sox2 can transform cells by suppressing the expression of Cux1.
Idea Proposed by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Tumorigenesis: Oct-4 and Sox2 suppress the expression of a new tumor suppressor gene CUX1 via induction of their target gene, 26/December/2013, 4.26 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
* Research cooperation